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Heparan sulfate proteoglycans mediate Aβinduced oxidative stress and
hypercontractility in cultured vascular
smooth muscle cells
Matthew R. Reynolds1†, Itender Singh1†, Tej D. Azad1, Brandon B. Holmes2, Phillip B. Verghese2, Hans H. Dietrich1,
Marc Diamond3, Guojun Bu4, Byung Hee Han5 and Gregory J. Zipfel1,2*

Abstract
Background: Substantial evidence suggests that amyloid-β (Aβ) species induce oxidative stress and cerebrovascular
(CV) dysfunction in Alzheimer’s disease (AD), potentially contributing to the progressive dementia of this disease.
The upstream molecular pathways governing this process, however, are poorly understood. In this report, we
examine the role of heparan sulfate proteoglycans (HSPG) in Aβ-induced vascular smooth muscle cell (VSMC)
dysfunction in vitro.
Results: Our results demonstrate that pharmacological depletion of HSPG (by enzymatic degradation with active,
but not heat-inactivated, heparinase) in primary human cerebral and transformed rat VSMC mitigates Aβ1-40- and
Aβ1-42-induced oxidative stress. This inhibitory effect is specific for HSPG depletion and does not occur with
pharmacological depletion of other glycosaminoglycan (GAG) family members. We also found that Aβ1-40 (but not
Aβ1-42) causes a hypercontractile phenotype in transformed rat cerebral VSMC that likely results from a HSPGmediated augmentation in intracellular Ca2+ activity, as both Aβ1-40-induced VSMC hypercontractility and
increased Ca2+ influx are inhibited by pharmacological HSPG depletion. Moreover, chelation of extracellular
Ca2+ with ethylene glycol tetraacetic acid (EGTA) does not prevent the production of Aβ1-40- or Aβ1-42mediated reactive oxygen species (ROS), suggesting that Aβ-induced ROS and VSMC hypercontractility occur
through different molecular pathways.
Conclusions: Taken together, our data indicate that HSPG are critical mediators of Aβ-induced oxidative stress
and Aβ1-40-induced VSMC dysfunction.
Keywords: Heparan sulfate proteoglycans, Alzheimer’s disease, Vascular smooth muscle cells, Cerebrovascular
dysfunction, Reactive oxygen species, Oxidative stress, Heparinase, Heparin
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Background
Alzheimer’s disease (AD) is a progressive amnestic
dementia characterized by the deposition of Aβ peptides
within the brain parenchyma and cerebrovasculature [1].
While the mechanisms underlying the development and
progression of AD remain enigmatic, a growing body of
evidence indicates that the pathologic effects of Aβ on
cerebral vessels likely play a critical role (for review, see
Ref. [2]). Specifically, soluble and insoluble forms of Aβ
have been shown to impair CV autoregulation [3–6], reduce cerebral blood flow (CBF) [3, 7, 8], and exacerbate
ischemic infarction [9–11]—deleterious effects that are
thought to contribute to the progressive dementia of
AD. Understanding the mechanisms of these Aβ − induced CV deficits is therefore essential to guide development of novel therapies.
Multiple lines of evidence indicate that Aβ − induced
CV deficits are mediated by reactive oxygen species (ROS)
(for review, see Ref. [12]). For instance, we have shown
that application of exogenous, soluble Aβ (Aβ1-40 and
Aβ1-42 monomers) onto isolated mouse cerebral arterioles leads to significant oxidative stress and vasomotor dysfunction, and that anti-ROS strategies
markedly improve these CV deficits [13]. Others have
shown that exogenous Aβ monomers applied to the
pial surface of live mice cause significant oxidative
stress and CV dysfunction, both of which can be
attenuated via a variety of anti-ROS interventions
[14–16]. Young Tg2576 mice having elevated levels of
endogenous soluble Aβ species display substantial
oxidative stress and CV deficits, both of which can be
inhibited by genetically eliminating the catalytic subunit Nox2 of NADPH oxidase (nicotinamide adenine
dinucleotide phosphate-oxidase – a major source of
ROS in cerebral vessels) [17]. Fibrillar Aβ in the form
of cerebral amyloid angiopathy (CAA) has also been
shown to promote CV dysfunction via ROS. First,
Garcia-Alloza et al. [18] observed that CAA-laden
vessels (but not CAA-free vessels) of aged Tg2576
mice develop severe oxidative stress. Second, Park et
al. [19] found that aged Tg2576 mice lacking the
Nox2 subunit of NADPH oxidase develop less oxidative
stress and no CV deficits compared to age-matched
control Tg2576 mice. Though the presence of CAA
and its effect on vessel function was not specifically
examined in this study, the fact that Tg2576 mice
were assessed at an age when CAA is expected [20]
suggested that NADPH oxidase-derived ROS may also
contribute to CAA-induced CV deficits. Third, we
recently reported that administration of the NADPH
oxidase inhibitor, apocynin, or the free radical scavenger,
tempol, to aged Tg2576 mice significantly improves CV
dysfunction and does so by decreasing CAA-induced
vasomotor impairment as well as reducing CAA
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formation itself [21]. As such, modulation of ROS and
identification of the upstream inducers of Aβ-mediated
ROS production will be instrumental for designing novel
therapies to prevent Aβ-induced CV dysfunction and the
impact these vascular deficits have on AD dementia.
Heparan sulfate proteoglycans (HSPG) are an attractive
upstream target of Aβ-induced ROS production and
CV dysfunction. HSPG are complex macromolecules
involved in diverse biological processes and are ubiquitously present on the cell surface and in the extracellular matrix [22]. Immunohistochemical studies of
post-mortem AD brain suggest that HSPG are associated
with the hallmark Aβ pathologies and correlate temporally
with Aβ deposition [23, 24]. In vitro experiments demonstrate that HSPG promote Aβ aggregation [25], stabilize
Aβ fibrils [26], and inhibit Aβ degradation [26]. HSPG
bind Aβ with high affinity and promote its intracellular uptake in multiple cell types [27], including
human cerebral vascular smooth muscle cells (VSMC)
[28]. In addition, pharmacological and/or genetic
depletion of HSPG prevents the intracellular uptake
of Aβ and resultant deposition both in vitro [29] and
in vivo [30]. These findings implicate HSPG as a key
contributor to Aβ metabolism and fibrillogenesis and
suggest that it may play a key role in ultimately the
development of AD. The role of HSPG in Aβ-induced
ROS production and CV dysfunction, however, has
yet to be examined.
To date, most studies examining the mechanisms of
Aβ-induced CV deficits have focused on the deleterious
interaction of Aβ on vascular endothelial cells (VEC)
(for review see Ref. [31]). Specifically, Aβ has been
shown to induce VEC dysfunction, leading to decreased
production of nitric oxide (NO; a potent endothelialderived vasodilator) and vascular hypercontractility [17].
Several studies, however, have shown that VSMC
dysfunction also plays a causal role in Aβ-induced CV
deficits, as enhanced ATP-induced constriction (an
VEC-independent response) was noted in isolated mouse
cerebral arterioles exposed to exogenous Aβ monomers
[13] and impaired responses to the VEC-independent
vasodilator SNAP was documented in young Tg2576
mice having elevated levels of endogenous soluble Aβ
(but no CAA) [6, 17]. Moreover, given the location of
fibrillar Aβ within the abluminal portion of the tunica
media surrounding VSMC in CAA-laden vessels [32, 33],
the VSMC architectural changes and frank cell death that
occurs in vessels with CAA deposits [6, 34]. The expectation that markedly elevated levels of soluble Aβ species
reside in close proximity to CAA deposits within the perivascular space [35], it is likely that VSMC dysfunction
plays an even greater role in CAA-induced CV deficits.
We therefore focused our experiments on VSMC as the
target of Aβ-mediated toxic effects in an effort to elucidate
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the upstream molecular events leading NADPH oxidase
activation, ROS production, and vascular cell dysfunction.

Methods
Reagents

Aβ peptides (Aβ1-40, Aβ40-1, and Aβ1-42) were purchased
from American Peptide Company (Sunnyvale, CA),
reconstituted in purified water, snap frozen over liquid
nitrogen and immediately utilized or stored at -80 °C for
no longer than two weeks prior to use. Chondroitinase B
and AC were purchased from IBEX Technologies Inc.
(Montreal, Quebec, Canada). Purified receptor-associated
protein (RAP) was a gift from Dr. Bu (Mayo Clinic, FL).
All other reagents, including heparinase enzymes (I and
III), were purchased from Sigma-Aldrich (St. Louis, MO).
Antibodies

The 82E1 (anti-Human Aβ mouse monoclonal antibody),
HJ2 (anti-human Aβ35–40) and HJ5-1 (an antibody that
selectively recognizes soluble, monomeric anti-human Aβ)
monoclonal antibodies were a gift from Dr. Holtzman
(Washington University in St. Louis, MO).
Cell culture

Primary human cerebral VSMC were purchased from
ScienCell Research Laboratories (Carlsbad, CA) and
grown according to the manufacturer’s instructions. To
confirm the data obtained from these cells, primary
human cerebral VSMC from another source (Cell
Biologics, Chicago, IL) were also used. All human VSMC
used in the present study were APOE e3/e3 allele. Transformed rat cerebral VSMC were also used, which were
kindly provided by Dr. Diglio, Wayne State University, MI)
[36, 37]. Rat cerebral VSMC were grown in Dulbecco’s
modified eagle’s medium (DMEM) supplemented with
10 % fetal bovine serum (FBS), 100 U/mL penicillin, and
100 μg/mL streptomycin sulfate. Rat VSMC cell line was
established from long-term serial cultures of adult rat brain
VSMC (mainly small pial arteries and arterioles). The
cell line has phenotypical and immunohistochemical
characteristics of VSMC. These cells were then infected
with Schmidt-Ruppin Rous sarcoma virus-strain D, an
arian retrovirus to induce immortality. This cell line
has proven to be a useful model for studying the specialized biochemical and functional properties of these
cells. Primary human cerebral VSMC cells were used
at passages 4 and maintained at 37 °C in humidified
air containing 5 % CO2.
ROS assay

Cells were plated onto 96-well black clear-bottomed
plates (Corning Inc. Life Sciences, Tewksbury, MA) at a
density of 50 × 103 cells/well the day prior to experiments. The day of experiments (cells density at near
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confluency), cells were washed gently for 10-15 seconds
with warmed (37 °C) Leibovitz’s media (L-15; no phenol
red indicator), loaded with the ROS-sensitive dye Mitotracker Red CM-H2XRos (MTR, final concentration of
5 μM; Molecular Probes, Eugene, OR) or dihydroethidium
(DHE, final concentration of 10 μM; Molecular Probes)
and incubated for 20-30 min. After incubation, cells were
washed with warm L-15 media and freshly prepared Aβ
peptides (dissolved in L-15 media) were added immediately before measurements at room temperature. In some
experiments, cells were co-treated with apocynin (10 μM)
and Aβ1-40 (2 μM). Fluorescence was measured at room
temperature with a plate reader (Synergy HTTR with KC4
software) over 30 min (λEx = 475 and λEm = 645 for MTR,
and λEx = 520 and λEm = 610 for DHE).
In some experiments, cells were pre-incubated with
heparin (15 U/mL), sodium chlorate (5-50 mM), active
or heat denatured (boiled at 100 °C for 20 min) heparinase I (5 Sigma units/mL) and heparinase III (2 Sigma
units/mL), chondroitinase AC (10-1 IU/mL), or chondroitinase B (10-1 IU/mL) in growth media for 2 h prior
to analysis. For neutralizing antibody experiments, cells
were pre-incubated with antibody (10 μg/mL) in growth
media for 2-3 h or co-treated with HJ5-1 antibody
(0.3 mg/mL) and Aβ1-40 (2 μM).
Intracellular Ca2+ activity assay

Human or rat VSMC were plated onto 96-well blackbottomed plates (Corning Inc. Life Sciences, Tewksbury,
MA) at a density of 50 × 103 cells/well the day prior to
the experiments. The day of experiments (cell density at
near confluency), cells were washed with warmed (37 °C)
L-15 media (no phenol red indicator), loaded with the
Fura II Ca2+-sensitive dye (Invitrogen, Molecular Probes,
Eugene, OR; 10 μM), and incubated at 37 °Cfor 2030 min. After incubation, cells were washed with L-15
media and freshly prepared Aβ peptides (dissolved in L-15
media) were added immediately before measurements. In
select experiments, cells were pre-treated with active or
heat denatured (boiled at 100 °C for 20 min) heparinase I
(5 Sigma units/mL). In other experiments, either an Ltype Ca2+ channel antagonist (diltiazem or verapamil;
10 μM) or the Ca2+ chelator ethylene glycol tetraacetic
acid (EGTA; 5 mM) was added to the extracellular media.
The addition of ionomycin to each sample well
(Sigma-Aldrich, St. Louis, MO; 2 μM) was used as a positive control for intracellular Ca2+ signal. Rat VSMC were
also treated with aminoethoxydiphenyl borate (2APB,
10 μM), an IP3-receptor inhibitor or ryanodine (1H-Pyrrole-2-carboxylic acid, 10 μM), a Ryanodine receptor
inhibitor.
The quantification of intracellular Ca2+ influx was
performed using ratiometric measurements as previously
described by Grynkiewicz et al. [38] with additional
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corrections for viscosity according to Poenie et al. [39]
The pH sensitivity of Fura II Ca2+-sensitive dye was
calculated using the method of Batlle et al. [40]. A
detailed description of the calculations for these measurements can be found in our previous work [41].
Analysis of Aβ peptides

Aβ1-40- and Aβ1-42-conditioned media (5 μM) was
removed from human cerebral VSMC cultures after a
30 min incubation at 37 °C and fractionated over a size
exclusion column (Superdex 200 10/300; 1 mL/min; GE
Healthcare Life Sciences, Piscataway, NJ) using fast
performance liquid chromatography (FPLC). The eluted
fractions were tested for the presence of Aβ using an
established enzyme-linked immunosorbent assay (ELISA)
[42]. Fractions containing Aβ peptide were further
analyzed by sodium dodecyl sulfate (SDS) and native
polyacrylamide gel electrophoresis (PAGE) and Western
blotting.
SDS- and native-PAGE

For denaturing conditions, samples were boiled in
Laemmli sample buffer (0.125 M Tris [pH 6.8], 4 % SDS,
20 % glycerol, and 10 % β-mercaptoethanol), loaded onto
a 16.5 % Tris-Tricine Criterion PreCast gel (BioRad Life
Science, Hercules, CA), resolved electrophoretically, and
transferred onto a nitrocellulose membrane. Membranes
were boiled in phosphate buffered saline for 5 min,
blocked with a 5 % (w/v) solution of non-fat dry milk in
tris buffered saline with tween (TBST), and then incubated for 16 h at 4 °C in a primary antibody solution
(82E1; 1 μg/mL). Following a secondary incubation with a
HRP-conjugated goat anti-mouse antibody (Jackson
ImmunoResearch, West Grove, PA), the membranes were
processed using enhanced chemiluminescence (Clarity
Western ECL Substrate; Biorad Life Science, Hercules,
CA) and protein bands were detected using the G:BOX
iChemi XT imaging system (Syngene, Frederick, MD). For
native conditions, samples were mixed with NativePAGE
sample buffer (Life Technologies, Carlsbad, CA), loaded
onto a Novex 4-20 % Tris-Glycine Native gel (Life Technologies, Carlsbad, CA), resolved electrophoretically, and
transferred onto nitrocellulose membranes. The remainder of the procedure was analogous to that performed for
denaturing conditions.
Cell surface area assay

Cells were grown in 48-well culture dishes, washed with
warmed L-15 media, and images were acquired with an
inverted light microscope (Nikon Eclipse E800; Nikon,
Melville, NY). Following a 30-min incubation at 37 °C
with varying Aβ preparations, additional light micrographs were obtained. In all instances, the experimenter
who acquired the micrographs was blinded to the
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treatment conditions. All cells were then treated with
warm L-15 media containing 100 mM potassium chloride (KCl) and cell surface area was measured at 1, 3, and
5 min after KCL addition, as described earlier [21].
Images were acquired from the same quadrant of each
well (near the center of the dish) to minimize variations
of cell layering at the culture dish periphery. All micrographs were processed using the Image J software package
(National Institute of Health website; www.imagej.nih.gov)
and cell surface area was quantified using the automatic
threshold function. Data was analyzed as % change in relative surface area units as compared to the vehicle-treated
control cells.
Immunoprecipitation of HSPG

Human VSMC cells were grown to near confluency in
100 mm petri dishes and treated with Aβ1-40 (2 μM) or
Aβ40-1 (2 μM) for 30 min. Cells were washed four times
with HBSS and cells were lysed with RIPA buffer. Cell lysates were immunoprecipitated with anti-Heparan Sulphate
Proteoglycan (Large) antibody (A7L6, Abcam). Samples
were immunoprecipitated using a Protein G immunoprecipitation kit (Roche Applied Sciences, Indianapolis, IN)
followed by SDS-PAGE separation and transfer onto nitrocellulose membranes (Millipore Corp). Immunoblotting
was performed by incubating the membrane with mouse
anti-Aβ antibody (6E10, Sigma). Following incubation the
corresponding secondary goat-anti-Rabbit HRP-conjugated
antibody (Santa Cruz Biotech) was used to detect immunoreactive product with chemiluminescent kit (BioRad).
Quantitative Polymerase Chain Reaction (qPCR)

Cells were grown to near confluency in 6-well plates,
washed with PBS, and total RNA was isolated using Trizol reagent (Life Technologies, Carlsbad, CA) followed
by synthesis of cDNA by reverse transcriptase using the
High Capacity cDNA Reverse Transcriptase Kit (Applied
Biosystems, Foster City, CA). Sense and antisense
oligonucleotides were designed for each HSPG subtype
(Additional file 1: Table S1) using a real-time PCR primer
design tool (Integrated DNA Technologies, Coralville, IA).
qPCR was performed using a 7500 real-time PCR System
(Applied Biosystems, Foster City, CA) and the reactions
were performed using SYBR Green PCR Master Mix
reagents (Applied Biosystems, Foster City, CA). GAPDH
expression was used as an internal loading control. Data
were analyzed using the delta-delta calculation method to
calculate fold change relative to controls [43].
Statistics

Determination of significance was accomplished by use
of a student’s two-tailed t test or ANOVA, depending on
the design of the experiment. The level of statistical
significance was set at 0.05.
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Results
Aβ1-40 and Aβ1-42 induce ROS production via NADPH oxidase

Previous reports have demonstrated that Aβ-induced
ROS is a critical mediator of CV dysfunction in vitro
[44], ex vivo [13], and in vivo [4–7, 17–19]. To examine
the effects of Aβ1-40 and Aβ1-42 on ROS production in
primary human cerebral VSMC, these cells were loaded
with a fluorescent dye sensitive for detecting mitochondrial ROS (Mitotracker Red CM-H2XRos), treated with
varying Aβ preparations, and assayed for ROS production
after 30 min. We observed a dose-dependent increase in
ROS with both Aβ1-40 and Aβ1-42 at micromolar, but not
nanomolar, concentrations (Fig. 1a, b). Treatment with a
scrambled control peptide (Aβ40-1) did not induce ROS
production. Co-treatment of cells with Aβ1-40 and the
NADPH oxidase inhibitor apocynin reduced ROS generation to baseline levels. Interestingly, at each concentration, Aβ1-42 was a more potent inducer of ROS
than Aβ1-40 in human cerebral VSMC (Fig. 1a, b). Apocynin is a non-specific inhibitor of Nox2. To more directly
determine whether Nox2 is involved in Aβ1-40 induced
ROS production, we performed a targeted genetic knockdown experiment in human VSMC using si-Nox2. We
found that genetic Nox2 inhibition significantly reduces
Aβ1−40-induced ROS (Fig. 1c), which indicates a direct
role of Nox2 in Aβ1-40-induced ROS production.
Several additional control experiments were performed
to determine the cellular consequences of Aβ1-40-induced ROS production, to examine the impact of apocynin on baseline ROS production, and to assess the
impact of physiological oxygen levels on Aβ1-40-induced
ROS production. To determine whether Aβ1-40-induced
ROS production produces toxic damage to cellular components, we quantified lipid oxidation levels following
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Aβ1-40 treatment. Human VSMC were exposed to Aβ1-40
for 24 h, followed by assessment of lipid oxidation via
measurement of thiobarbituric acid reactive substance
(Additional file 2: Figure S1). We found that Aβ1-40 significantly increases lipid peroxidation - a finding consistent with true Aβ1-40-induced oxidative stress. To assess
whether apocynin impacts baseline ROS production in
VSMC, we treated human VSMC with apocynin alone
(without Aβ1-40) and found that baseline ROS levels
were not impacted (Additional file 3: Figure S2). To
determine if differing levels oxygen impact ROS production in Aβ1-40 treated VSMC, we performed an experiment using 10 % oxygen (conditions that are considered
physiologic [45]) and an experiment using 1 % oxygen
(conditions that are hypoxic) and compared these results
to our experiments where VSMCs were grown in humidified air containing 5 % CO2 (conditions that are not
physiologic, but are very commonly used in the field
[13]). We found that Aβ1-40 induces significant ROS
production in cultured VSMCs under both conditions,
but that ROS production was greater with 10 % oxygen (Additional file 4: Figure S3A) than 1 % oxygen
(Additional file 4: Figure S3B).
Given the tendency of monomeric Aβ to polymerize
into oligomers and fibrils over time, we analyzed VSMC
conditioned media from the Aβ1-40- and Aβ1-42-treated
(5 μM) samples after 30 min to assess higher order
species. Aβ species from VSMC conditioned media were
loaded onto a size exclusion chromatography column
and fractionated via FPLC. Aβ-containing fractions were
detected using ELISA, and those fractions were further
analyzed by SDS- and native-PAGE. We found that the
majority of Aβ1-40 was in monomeric form with minor
amounts (<10 %) of higher order, SDS soluble aggregates

Fig. 1 Soluble, monomeric Aβ induces a dose-dependent increase in ROS in primary human cerebral VSMC. VSMC were loaded with Mitotracker
Red CM-H2XRos (5 μM) and treated with varying concentrations of Aβ1-40 (panel a) or Aβ1-42 (panel b). In some cases, cells were treated with a
scrambled control peptide (Aβ40-1) or co-treated with the NADPH oxidase inhibitor apocynin (Apo; 10 μM, panel a-b) or siRNA against Nox2
(panel c) and Aβ. Fluorescence was measured after 30 minutes. Results are representative of 3 independent experiments performed in triplicate.
*p < 0.05 vs. vehicle-treated control. #p < 0.05 vs. comparison group
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(Additional file 5: Figure S4A, B). Similarly, the Aβ1-42
sample was mostly in monomeric form with minor
amounts (< 15-20 %) of higher order, SDS soluble aggregates (Additional file 5: Figure S4C, D). To specifically
differentiate monomers vs. oligomers in the media, we
utilized an oligomer-specific anti- Aβ antibody (A11).
We found that the majority of Aβ remains as monomers in our experimental conditions; however, we do
detect a very small amount of oligomers (Additional
file 5: Figure S4E).
Aβ1-40-induced ROS production is attenuated by targeted
inhibition of HSPG

HSPG are present in both the extracellular matrix (agrin,
perlecan, and collagen XVIII) and the cell surface (glypicans 1-6 and syndecans 1-4) [22]. To assess which HSPG
subtypes are present in human cerebral and rat cerebral
VSMC, we harvested RNA from cell culture lysates and
quantified mRNA using qPCR. In human and rat cerebral
VSMC, we found that while all HSPG subtype mRNAs
were detectable, they were expressed to very different
levels (Additional file 6: Figure S5A, B). While greater
levels of agrin, perlecan, glypican 1, syndecan 2, syndecan
3 and keratan sulfate mRNA were present in human vs.
rat VSMC, greater levels of collagen XVIII, glypican 3, glypican 4, glypican 6, syndecan 1, syndecan 4 and chondroitin sulphate mRNA were present in rat vs. human VSMC.
Given the known interaction of several HSPG subtypes
with Aβ [22, 24], we hypothesized that HSPG could be
involved in Aβ-induced ROS production.
Low molecular weight heparin administration has previously been shown to prevent Aβ internalization in cultured
cells in vitro [29] and attenuate Aβ-mediated inflammation
and neurotoxicity in vivo [46], likely through a HSPGdependent mechanism [47]. For this reason, we examined
whether heparin could mitigate ROS production in cultured human cerebral VSMC. Given that heparin can
directly bind Aβ and also exhibits pleotropic cellular effects
[48], cells were pre-treated with heparin (15 U/mL),
washed, loaded with Mitotracker Red CM-H2XRos dye,
and treated with Aβ1-40 (2 μM). We observed that heparin
pre-treatment markedly reduced Aβ-mediated ROS
production (Fig. 2a), suggesting a possible contributing role
of HSPG.
To more directly implicate HSPG in Aβ-induced ROS
production, we pre-treated cells with either active or
heat denatured heparinase I (5 Sigma U/mL) and heparinase III (2 Sigma U/mL) followed by washout and ROS
measurements. Heparinase is a mammalian endo-β-Dglucuronidase that specifically cleaves heparan sulfate,
thereby preventing Aβ-HSPG interactions. We found
that pre-incubation with active, but not heat inactivated,
heparinase I and III significantly reduced Aβ1-40-mediated ROS production (Fig. 2b). We documented similar
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results after repeating this experiment with VSMC
from another source (Cell Biologics, Additional file 7:
Figure S6). When these experiments were performed
using the fluorescent dye dihydroethidium (DHE; a
sensitive indicator of cytosolic superoxide oxygen
species), we obtained comparable results (Fig. 2c),
suggesting that Aβ-mediated ROS production occurs
in both the mitochondria and cytosol.
To determine if HSPG directly interact with Aβ1-40,
human VSMC cells were treated with Aβ1-40 for
30 minutes and cell lysates were immunoprecipitated
with anti-HSPG antibody and immunoblotted with
anti-Aβ antibody. Immunoblot showed the presence
of Aβ in immunoprecipitated fractions, which suggests direct interaction of Aβ with HSPG (Fig. 2d).
When coupled with the aforementioned pharmacologic experiments targeting HSPG, these data provide
further evidence that Aβ1-40 plays a key role in mediating VSMC cellular dysfunction.
Finally, we pre-treated cells with increasing concentrations of sodium chlorate, which blocks proper
sulfation of HSPG. We found that sodium chlorate
reduces Aβ-induced oxidative stress in human
VSMC in a dose-dependent fashion (Fig. 3b). This
observation is likely caused by the inability of Aβ1-40
to effectively interact with non-sulfated HSPG side
chains.
In total, our results that Aβ-mediated ROS production
is attenuated by three separate HSPG-targeted interventions—heparin that competitively inhibits HSPG; heparinase I or heparanase III that cleave heparan sulfate
moieties of HSPG; and sodium chlorate that inhibits sulfation of HSPG side chains—strongly indicate that
HSPG are a key mediator of the vascular oxidative stress
caused by Aβ.

Aβ1-40-induced ROS production is unaffected by targeted
inhibition of other glycosaminoglycan family members

In theory, Aβ could bind either HSPG or other surface proteins, such as chondroitin sulfate proteoglycans and dermatin sulfate proteoglycans. To examine
whether enzymatic disruption of other glycosaminoglycan (GAG) family members affects Aβ-mediated
ROS elaboration, we pre-treated human cerebral
VSMC with active and heat denatured chondroitinase
B (which selectively degrades dermatin sulfate) and
chondroitinase AC (which selectively degrades chondroitin sulfate) prior to washout and ROS assessment.
Our results demonstrate that neither dermatin sulfate
nor chondroitin sulfate participate in Aβ-mediated
oxygen radical production (Fig. 3a), supporting the
notion that Aβ1-40 selectively interacts specifically
with HSPG to promote oxidative stress.
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Fig. 2 Pharmacological knockdown of HSPG mitigates Aβ1-40-induced mitochondrial and cytosolic ROS production in VSMC. Primary human
cerebral VSMC were pre-treated with heparin (15 U/mL), heparinase I (HpnI; 5 Sigma U/mL), or heparinase III (HpnIII; 2 Sigma U/mL) for 2 h,
washed, loaded with Mitotracker Red CM-H2XRos (MTR; 5 μM; panels a, b) or the cytosolic superoxide-sensitive dye dihydroethidium (10 μM;
panel c), washed, and treated with Aβ1-40. In some cases, cells were pre-treated with heat-inactivated (HI) enzyme (at the same concentration of
active enzyme) and washed prior to MTR loading and Aβ treatment. Fluorescence was measured after 30 minutes. To determine if HSPG directly
interact with Aβ1-40, human VSMC cells were treated with Aβ1-40 for 30 minutes and cell lysates were immunoprecipitated with anti-HSPG antibody
and immunoblotted with anti-Aβ antibody (Panel d). Results are representative of 3 independent experiments performed in triplicate. *p < 0.05 vs.
vehicle-treated control. #p < 0.05 vs. comparison group

Aβ1-40-induced VSMC dysfunction is attenuated by
targeted inhibition of HSPG

Soluble, monomeric Aβ is a vasoactive peptide that exhibits significant vasoconstrictive properties [6, 49, 50].
The preponderance of data suggests that Aβ1-40—the
species that primarily comprises the fibrillar deposits of
CAA—is a more potent vasoconstrictor than Aβ1-42
[51, 52]. To delineate the effects of Aβ treatment on
cultured rat cerebral VSMC contractile function, cell
surface area was measured after 30 min via light microscopy after treatment with varying Aβ preparations. Of note, rat cerebral VSMC were used instead
of human cells because we were unable to reliably
quantitate changes in human cerebral VSMC morphology in response to various stimuli given their rigid

adherence to the culture dish. However, we verified
that rat cerebral VSMC are similar to human cerebral
VSMC with respect to Aβ1-40-induced ROS production
and abrogation of Aβ1-40-induced oxidative stress by
pharmacological HSPG knockdown (Additional file 8:
Figure S7A, B), though the magnitude of ROS production
was different (likely the result of a species-specific effect).
In agreement with prior studies [21], we observed a
12 % decrease in cell surface area following treatment
with Aβ1-40, but not with the Aβ1-42 or Aβ40-1 scrambled
peptide (Fig. 4a). Also, co-treatment of cells with Aβ1-40
and apocynin did not significantly change VSMC surface
area relative to cells treated with Aβ1-40 alone. This observation suggests that in rat cerebral VSMC, inhibition
of ROS formation does not necessarily prevent Aβ-

Fig. 3 Pharmacological knockdown of other glycosaminoglycan (GAG) family members does not affect Aβ1-40-mediated ROS production in VSMC.
Primary human cerebral VSMC were pre-treated with chondroitinase B (10-1 IU/mL; selectively degrades dermatin sulfate; panel a), chondroitinase
AC (10-1 IU/mL; selectively degrades chondroitin sulfate; panel a), or varying concentrations of the sulfation inhibitor sodium chlorate (5-50 mM;
panel b) for 2 h, washed, loaded with Mitotracker Red CM-H2XRos (MTR; 5 μM), and treated with Aβ1-40. In some cases, cells were pre-treated with
heat-inactivated (HI) enzyme (at the same concentration of active enzyme) and washed prior to MTR loading and Aβ treatment. Fluorescence
was measured after 30 minutes. Results are representative of 3 independent experiments performed in triplicate. *p < 0.05 vs. vehicle-treated
control. #p < 0.05 vs. comparison group
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Fig. 4 Pharmacological knockdown of HSPG prevents Aβ1-40-mediated VSMC constriction. Transformed rat cerebral VSMC surface area was measured
via light microscopy 30 minutes after the addition of varying Aβ preparations (panel a). In some cases, cells were pre-treated with heparinase I (HpnI; 5
Sigma U/mL) or heat-inactivated heparinase I (HI HpnI; 5 Sigma U/mL) for 2 h, washed, and treated with Aβ1-40 (panel b). In other cases, cells were
co-treated with the NADPH oxidase inhibitor apocynin (10 μM) and Aβ1−40. After 30 minutes, cells were treated with KCl (100 mM) and surface area
was measured at 1, 3, and 5 minutes (panel c, d). Panel c: light micrographs at 0, and 5 minutes after vehicle; Inset: light micrographs at 0, 1, and
5 minutes after KCl addition (scale bar = 10 μM). *p < 0.05 vs. vehicle-treated control. #p < 0.05 vs. comparison group. The arrows represent individual
cells undergoing a phenotypical change (e.g., vasoconstriction) following Aβ1-40 treatment

mediated VSMC constriction. Pre-incubation of cells
with active—but not heat denatured—heparinase I
enzyme (5 Sigma U/mL) followed by washout and treatment with Aβ1-40 effectively reversed the Aβ1-40-induced
hypercontractile phenotype (Fig. 4b). After 30 minutes,
cells were treated with KCl (100 mM) to open cell
surface voltage-gated calcium channels [53] and VSMC
surface area was measured over an additional 5 minutes.
We found that VSMC initially treated with Aβ1-40, apocynin + Aβ1-40, and heat inactivated heparinase I + Aβ1-40
all reduced VSMC surface area after KCl treatment relative to the vehicle-treated control at 3 and 5 minutes
(Fig. 4c-d). Conversely, rat cerebral VSMC initially
treated with Aβ1-40 + heparinase I followed by treatment
with KCl responded similarly to the vehicle-treated control at 3 and 5 minutes (Fig. 4c-d).
Potential role of Ca2+ in Aβ1-40-induced VSMC dysfunction

To examine the role of Ca2+ in the regulation of Aβ1-40and Aβ1-42-induced ROS production and Aβ1-40-induced

VSMC hypercontractility, we utilized the Ca2+-sensitive
dye Fura II to measure changes in intracellular Ca2+
levels. Rat cerebral VSMC were loaded with Fura II,
washed, and then treated with varying concentrations of
Aβ1-40 and Aβ1-42. We observed that intracellular Ca2+
influx increased as a function of Aβ1-40 concentration
over ~10 minutes, with the maximum level of intracellular Ca2+ achieved after treatment with Aβ1-40 at 2 μM
concentrations (Fig. 5a). Interestingly, even at higher
concentrations, the level of intracellular Ca2+ achieved
after treatment of cells with Aβ1-42 was well below that
of cells treated with Aβ1-40 (Fig. 5b). Co-treatment of rat
cerebral VSMC with the NADPH oxidase inhibitor
apocynin did not reverse Aβ1-40-mediated Ca2+ influx
(Fig. 5c).
Next, we examined the route(s) by which Ca2+ enters
the intracellular space following Aβ1-40 treatment in
VSMC. We found that Ca2+ does not enter through Ltype Ca2+ channels given that the L-type Ca2+ channel
blockers verapamil and diltiazem did not decrease

Reynolds et al. Molecular Neurodegeneration (2016) 11:9

Page 9 of 15

Fig. 5 Aβ1-40, but not Aβ1-42, induces Ca2+ influx into VSMC and this Ca2+ influx does not occur through L-type Ca2+ channels. Transformed rat
cerebral VSMC were loaded with fura II (10 μM) and treated with varying concentrations of Aβ1-40 (panel a) or Aβ1-42 (panel b). In some cases, cells
were treated with a scrambled control peptide (Aβ40-1; panel a) or co-treated with the NADPH oxidase inhibitor apocynin (Apo; 10 μM) and Aβ1-40
(panel c). In other experiments, cells were co-treated with an L-type Ca2+ channel antagonist (either verapamil or diltiazem; 10 μM) and Aβ1-40, or
treated with Aβ1-40 in the presence or absence of the Ca2+ chelator EGTA (5 mM; panel d). Rat VSMC were also treated with aminoethoxydiphenyl
borate (2APB, 10 μM), an IP3-receptor inhibitor or ryanodine (1H-Pyrrole-2-carboxylic acid, 10 μM), a Ryanodine receptor inhibitor (panel e). In some
experiments, cells were pre-treated with active or heat-inactivated heparinase I (HpnI; 5 Sigma U/mL), washed, loaded with fura II, and treated with
Aβ1−40 (panel f). Fluorescence was measured over ~10 minutes. Results are representative of 3 independent experiments performed in triplicate.
*p < 0.05 vs. vehicle-treated control

intracellular Ca2+, but co-incubation with the extracellular
Ca2+ chelating agent EGTA produced a marked decrement in intracellular Ca2+ (Fig. 5d). We did find that 1)
treatment with aminoethoxydiphenyl borate (2APB), an
IP3-receptor inhibitor, decreased the Aβ1-40-induced rise
in intracellular Ca2+ (Fig. 5e) and 2) treatment with
ryanodine (1H-Pyrrole-2-carboxylic acid), a Ryanodine
receptor inhibitor, induced a small inhibition of the

Aβ1-40-induced rise in intracellular Ca2+ (Fig. 5e). In
total, these data indicate Aβ1-40 treatment likely stimulates
the release of Ca2+ into the intracellular space via IP-3
receptors. Non-specific Ca2+ entry through the cell
membrane is also possible.
We also examined whether HSPG mediate the Ca2+
influx observed following Aβ1-40 treatment in rat and
human VSMC. We found that pre-incubation of rat
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cerebral VSMC with active, but not heat-inactivated, heparinase I attenuated Aβ1-40-induced Ca2+ influx (Fig. 5f ).
Using ratiometric quantification of intracellular Ca2+, we
observed that treatment of rat cerebral VSMC with Aβ1-40
(2 μM) resulted in a 216.1 ± 13.0 nM increase in intracellular Ca2+ as compared to a 58.0 ± 3.7 nM increase with
vehicle treatment alone (p < 0.001). Pre-treatment of rat
cerebral VSMC with active heparinase I resulted in a
significant reduction of Aβ1-40-induced Ca2+ influx as
compared to pre-treatment with vehicle alone (91.6 ± 3.3
vs. 216.1 ± 13.0 nM, respectively; p < 0.001), but did not
completely return the level of intracellular Ca2+ concentration to that of vehicle treatment alone (91.6 ± 3.3 vs.
58.0 ± 3.7 nM, respectively; p < 0.001). Notably, pretreatment of rat cerebral VSMC with heat-inactivated heparinase I resulted in an increase in Aβ1-40-induced Ca2+
influx as compared to pre-treatment with active heparinase I (180.4 ± 8.4 vs. 91.6 ± 3.3 nM, respectively; p <
0.001). We also found a similar (albeit less pronounced)
HSPG-mediated effect of Aβ1-40 on Ca2+ influx in human
VSMC (Additional file 9: Figure S8). Collectively, these
data suggest that pharmacological interference with HSPG
attenuates Aβ1-40-induced increases in intracellular Ca2+
in rat and human cerebral VSMC.
To determine whether intracellular Ca2+ influx is required for Aβ1-40 and Aβ1-42-induced ROS production,
we co-incubated rat cerebral VSMC with EGTA and
assayed for ROS production after 30 minutes following
treatment with either Aβ1-40 or Aβ1-42. Our results show
that Ca2+ influx may not be essential for either Aβ1-40or Aβ1-42-induced ROS production as EGTA failed to
inhibit amyloid-induced ROS (Fig. 6a). We found that
Aβ1-40-mediated ROS production requires incubation of
at least ~30 minutes (Fig. 6b), however, Aβ1-40-induced
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Ca2+ influx and VSMC hypercontractility occur within
5 minutes following Aβ1-40 treatment (Fig. 6c).

Discussion and conclusions
Our results demonstrate that (1) Aβ1-40 and Aβ1-42 (but
not the scrambled peptide Aβ40-1) induce ROS production
in cultured human cerebral VSMC in a dose-dependent
fashion; (2) Aβ1-40- and Aβ1-42-induced ROS production is
mediated downstream by NADPH oxidase activation, as
co-treatment with the NADPH oxidase inhibitor apocynin
or co-treatment with siRNA targeting Nox2 mitigated Aβinduced ROS production in cultured human cerebral
VSMC; (3) Aβ1-40- and Aβ1-42-induced ROS production is
mediated via HSPG, as pre-treatment with heparin, heparinase (I and III), and sodium chlorate prevents Aβinduced ROS production in cultured human cerebral
VSMC and knockdown of other GAG family members (as
well as antibody-mediated interference with other known
Aβ binding partners on the cell surface) did not recapitulate this protective effect; (4) Aβ1-40, but not Aβ1-42,
induces a hypercontractile phenotype in cultured rat
VSMC—an effect that is dependent on HSPG but not
NADPH oxidase, as Aβ1-40-induced VSMC hypercontractility was reversed when cells were pre-incubated with heparinase I but not when cells were co-treated with
apocynin; and (5) Aβ1-40, but not Aβ1-42, induces HSPGdependent Ca2+ influx that appears to underlie the pathologic effect of Aβ1-40 on VSMC function, as Aβ1-40 causes
Ca2+ influx into cultured rat VSMC that coincides
temporally with Aβ1-40-induced VSMC hypercontractility.
Importantly, both Aβ1-40-induced VSMC dysfunction and
Aβ1-40-induced Ca2+ influx appear mediated via HSPG, as
pre-incubation with heparinase I attenuated both events.
Overall, our data not only confirm past studies that show

Fig. 6 Aβ1-40- and Aβ1-42-mediated ROS production is not dependent on intracellular Ca2+ influx. Transformed rat cerebral VSMC were loaded
with Mitotracker Red CM-H2XRos (5 μM) and treated with either Aβ1-40 or Aβ1-42 in the presence or absence of EGTA (5 mM) in the extracellular
media (panel a). Aβ1-40-mediated ROS production in VSMC was measured after 5 minutes and compared with ROS production after 30 minutes
(panel b). Aβ1-40-mediated changes in VSMC surface area were measured after 5 minutes and compared with VSMC surface area after 30 minutes
(panel c)
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Aβ species induce vascular oxidative stress via NADPH
oxidase, but extend upon them by shedding important
mechanistic insight into the upstream molecular events by
which Aβ-induced ROS production and Aβ-induced
VSMC dysfunction occur. Specifically, our data strongly
implicate HSPG as a key mediator of Aβ1-40- and Aβ1-42induced VSMC oxidative stress, Aβ1-40-induced VSMC
hypercontractility, and Aβ1-40-induced Ca2+ influx (Fig. 7).
These results are important for a number of reasons.
First, multiple lines of evidence indicate that vascular
pathologies including Aβ have significant and independent
contributions to the dementia of AD, a realization that has
led the American Heart Association [54], the Alzheimer’s
Association [55], and the National Institute on Neurological Disorders and Stroke [56] to prioritize studies
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investigating the nature and mechanisms of vascular
contributors to dementia. Second, while oxidative stress
has been linked to the CV dysfunction caused by Aβ species in a variety of in vitro [13], ex vivo [13], and in vivo
[4–7, 17–19] experimental paradigms, the upstream molecular events leading to this vascular oxidative stress are
poorly understood. Identification of these events would
likely lead to discovery of novel molecules that that could
serve as new therapeutic targets for patients with AD,
CAA, or both. Our results implicating HSPG as a key mediator of Aβ-induced oxidative stress and Aβ1-40-induced
VSMC dysfunction strongly suggest that this cell surface
molecular complex represents a new pharmacologic target
deserving of additional investigation. Third, while our
study concentrated on the pathologic effects of two

Fig. 7 Schematic illustrating the cascade of intracellular events culminating in Aβ-induced Ca2+ influx, ROS production, and VSMC contractility. Aβ
(in either monomeric, oligomeric, or fibrillar form) may interact with cell surface or extracellular matrix HSPG, leading to intracellular Ca2+ influx
(early event, ~2 mins) and ROS production (later event, ~30 mins). Toxic ROS species may directly damage the VSMC contractile machinery
leading to a hypercontractile phenotype. Also, via an independent or interdependent pathway, intracellular Ca2+ may bind to calmodulin to
activate myosin light chain kinase (MLCK) and facilitate VSMC contraction. Interference with Aβ-HSPG binding via treatment with heparin or
heparinase can mitigate these toxic effects of Aβ
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monomeric forms of Aβ (Aβ1-40 and Aβ1-42) on one vascular cell type (VSMC), our results may well have mechanistic implications on other forms of Aβ-induced CV
dysfunction including that caused by vascular endothelial
cell (VEC) dysfunction and that caused by higher order
Aβ species. Support for the former comes from in vitro,
ex vivo, and in vivo studies that implicate ROS in Aβinduced VEC dysfunction [13, 17, 57] and VEC-mediated
vasomotor impairment; [13, 17, 57–59] support for the
latter comes from in vitro and in vivo studies demonstrating that oligomeric Aβ (at least in neurons) [60] and fibrillar Aβ (in cerebral vessels and neurons) [18, 61–65] cause
even greater degrees of oxidative stress. Therefore, while
elevated levels of soluble Aβ—and their attendant vascular
consequences including altered CV reactivity [6] and
impaired CBF [49, 50]—are present in the early stages
of AD when fibrillar Aβ in the form of neuritic plaques
and CAA have yet to develop to a significant degree, the
mechanisms elucidated in our study may very well
exert their greatest impact on the later stages of AD
when higher order Aβ species are much more abundant. Future studies will be required to examine this
intriguing possibility.
One interesting and at first counterintuitive observation
from our results is that while exogenous Aβ1-42 application
induces ROS production somewhat more effectively than
Aβ1-40 in cultured human and rat VSMC, only Aβ1-40
generates a hypercontractile phenotype in rat VSMC. The
most plausible explanation for this finding is that Aβ1-40
induces an influx of intracellular Ca2+ much more effectively than Aβ1-42 (a notion supported by our data; see
Figs. 5 and 6), and that Aβ-mediated ROS production and
Aβ-mediated Ca2+ influx may contribute to CV dysfunction via independent, or interdependent, processes. Our
data support a scenario whereby Aβ monomers interact
with cell surface and/or extracellular matrix HSPG leading
to an early intracellular Ca2+ influx (~2 min) and a later
elaboration of ROS species (~30 min) (Fig. 6). These toxic
ROS may subsequently direct damage to the VSMC contractile machinery, thereby leading to a hypercontractile
phenotype. In addition, through an independent or interdependent process, intracellular Ca2+ may contribute to
Aβ-induced VSMC dysfunction by binding to calmodulin
and activate myosin light chain kinase to facilitate VSMC
contraction (Fig. 7). Determining which of these two processes is the primary driver of Aβ-induced VSMC dysfunction, and assessing whether either process is dependent on
the other will require additional experiments. However,
our initial studies indicate the following: 1) Ca2+ influx
does not appear necessary for either Aβ1-40- or Aβ1-42-induced ROS production in VSMC (Fig. 6a); and 2) Aβ1-40induced VSMC hypercontractility appears to temporally
coincide with Aβ1-40-induced Ca2+ influx and precede
significant Aβ1-40-mediated ROS production (Fig. 6b, c). As
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such, it may be that intracellular Ca2+ activity—rather than
intracellular ROS—is the primary driver Aβ1-40-induced
VSMC dysfunction.
That interference with Aβ-HSPG binding via treatment
with heparin, heparinase, or sodium chlorate mitigated
both of these Aβ-induced toxic effects argues strongly for
the concept that HSPG-directed therapies carry promise
as a new approach towards combating the consequences
of Aβ-induced CV dysfunction in patients with AD, CAA,
or both. Another interesting observation from our data
was that apocynin co-treatment of VSMC reduced Aβmediated ROS production (Fig. 1) but did not rescue these
cells from a hypercontractile phenotype (Fig. 4). These
data seem to conflict with our prior observation in
explanted rat cerebral arterioles that strategies aimed to
reduce ROS were effective in reversing the Aβ-mediated
hypercontractile response [13]. Most likely, this observation relates to the differing experimental models utilized
in our two studies. In the present report, we utilized
isolated VSMC monocultures that permit direct measurement of VSMC function, while in our former study [13]
we employed isolated cerebral arterioles that permit
assessment of both VEC-dependent as well as VECindependent vasomotor function. It is plausible that Aβmediated ROS production has a greater functional impact
on VEC than on VSMC, which explain our [13] and
others [17, 19] past findings that vascular oxidative stress
is an important mediator of Aβ-induced CV dysfunction
in the setting of intact vessels (ex vivo and in vivo).
Our study has several limitations. First, our experiments were performed in tissue culture and may not be
generalized to the ex vivo or in vivo settings. Second,
our experiments focused solely on the role of Aβmediated toxic effects in cultured VSMC. To address
both of these limitations, we are currently performing
experiments to determine the role of HSPG in the
oxidative stress and functional consequences of Aβ in
cultured VEC and Aβ applied to isolated cerebral vessels.
Third, while fibrillar Aβ in the form of CAA is
commonly present in the smooth muscle cell layer of
cerebral arterioles, it is possible that monomeric Aβ may
not be present in this compartment at μM concentrations. While the concentration of Aβ in the serum and
cerebrospinal fluid has been estimated in the nM range
[66], recent evidence suggests soluble Aβ species are in a
dynamic equilibrium with fibrillar Aβ deposits in brain
and cerebral vessels [35] which would allow for higher
local concentrations of Aβ in brain regions immediately
surrounding fibrillar Aβ deposits. Therefore, it is entirely
possible that the local concentration of monomeric Aβ
in the perivascular space is significantly higher (e.g., μM,
or even mM), thereby validating the physiological
relevance of the Aβ concentrations that we chose for
our experiments.
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Additional files
Additional file 1: Table S1. Heparin sulfate proteoglycan (HSPG) primer
pairs for quantitative polymerase chain reaction (qPCR). (DOCX 20 kb)
Additional file 2: Figure S1. Soluble, monomeric Aβ1-40 induces lipid
oxidation in human VSMC. Human VSMC were exposed to Aβ1-40 for
24 h, followed by assessment of lipid oxidation via measurement of
thiobarbituric acid reactive substance (TBARS). In parallel experiments
primary human cerebral VSMC were also pre-treated with heparinase I
(HpnI; 5 Sigma U/mL). Results are representative of 3 independent
experiments performed in triplicate. *p < 0.05 vs. vehicle-treated control.
#p < 0.05 vs. comparison group. (JPEG 28 kb)
Additional file 3: Figure S2. Apocynin does not impact baseline ROS
production in VSMC. Human VSMC were loaded with Mitotracker Red
CM-H2XRos (5 μM) and treated with Aβ1-40. In some cases, cells were
co-treated with the NADPH oxidase inhibitor apocynin (Apo; 10 μM).
Fluorescence was measured after 30 minutes. Results are representative
of 3 independent experiments performed in triplicate. *p < 0.05 vs.
vehicle-treated control. #p < 0.05 vs. comparison group. (JPEG 31 kb)
Additional file 4: Figure S3. HSPG mitigates Aβ1-40-induced
mitochondrial and cytosolic ROS production in VSMC under physiological
oxygen concentration. To determine if differing levels oxygen impact
ROS production in Aβ1-40 treated VSMC, cells were kept in 10 % oxygen
(Panel A) or 1 % oxygen (conditions that are considered hypoxic; Panel B)
in cell culture incubator with % 5 CO2. Primary human cerebral VSMC
were pre-treated with heparin (15 U/mL), heparinase I (HpnI; 5 Sigma U/
mL), or heparinase III (HpnIII; 2 Sigma U/mL) for 2 h, washed, loaded with
Mitotracker Red CM-H2XRos, washed, and treated with Aβ1-40. In some
cases, cells were pre-treated with heat-inactivated (HI) enzyme. Fluorescence
was measured after 30 minutes. Results are representative of 3 independent
experiments performed in triplicate. *p < 0.05 vs. vehicle-treated control.
#p < 0.05 vs. comparison group. (JPEG 70 kb)
Additional file 5: Figure S4. Aβ1-40 and Aβ1-42 remain mostly in soluble,
monomeric form after 30 minute incubation in L-15 media. Conditioned
media from Aβ1-40- (panels A, B) and Aβ1-42-treated VSMC (5 μM) was
loaded onto a size exclusion column and fractionated via fast performance
liquid chromatography (FPLC). Aβ-containing fractions were identified using
enzyme-linked immunosorbent assays (ELISA) and higher-order Aβ species
were separated from monomer (4 kDa) by SDS- (panels A, C) and native(panels B, D) polyacrylamide gel electrophoresis (PAGE) with Western
blotting. Aβ1-40 and Aβ1-42 peptides were detected using the anti-Human
Aβ mouse 82E1 monoclonal antibody (1 μg/mL). To specifically differentiate
monomers vs. oligomers in the media, we performed dot blot using
oligomer-specific anti- Aβ antibody (A11; Panel E). (JPEG 75 kb)
Additional file 6: Figure S5. HSPG subtype mRNA is present in primary
human cerebral and transformed rat cerebral VSMC. HSPG subtype mRNA
was harvested from primary human cerebral as well as transformed rat
cerebral VSMC and measured using quantitative polymerase chain
reaction (qPCR). Extracellular matrix HSPG include agrin, perlecan, and
collagen XVIII; cell surface HSPG include glypicans 1-6 and syndecans 1-4
(Panel A). In addition we also performed qPCR for chondroitin sulphate,
dermatan sulphate and keratan sulfate (Panel B). *p < 0.05 vs. comparison
group. (JPEG 90 kb)
Additional file 7: Figure S6. Human VSMC cells from second source
conform that HSPG mitigates Aβ1-40-induced mitochondrial and cytosolic
ROS production in VSMC. Primary human cerebral VSMC from other source
(Cell Biologics, Chicago, IL) were pre-treated with heparin (15 U/mL),
heparinase I (HpnI; 5 Sigma U/mL), or heparinase III (HpnIII; 2 Sigma U/mL)
for 2 h, washed, loaded with Mitotracker Red CM-H2XRos (MTR; 5 μM),
washed, and treated with Aβ1-40. In some cases, cells were pre-treated with
heat-inactivated (HI) enzyme. Fluorescence was measured after 30 minutes.
Results are representative of 3 independent experiments performed in
triplicate. *p < 0.05 vs. vehicle-treated control. #p < 0.05 vs. comparison
group. (JPEG 42 kb)
Additional file 8: Figure S7. Transformed rat cerebral VSMC behave
similarly to human cerebral VSMC with respect to Aβ1-40-induced ROS
production and mitigation of Aβ1-40-induced oxidative stress by
pharmacological knockdown of HSPG with heparinase. Rat cerebral VSMC

Page 13 of 15

were loaded with Mitotracker Red CM-H2XRos (5 μM) and treated with
varying concentrations of Aβ1-40 or a scrambled control peptide (Aβ40-1;
panel A). In some experiments, cells were pre-treated with heparinase
(or heat-inactivated enzyme) for 2 h, washed, and then treated with
Aβ1-40 (2 μM) (panel B). Fluorescence was measured after 30 minutes.
Results are representative of 3 independent experiments performed in
triplicate. Apo = apocynin. Hpn = heparinase. HI = heat inactivated.
*p < 0.05 vs. vehicle-treated control. #p < 0.05 vs. comparison group.
(JPEG 56 kb)
Additional file 9: Figure S8. Human VSMC cells also show Aβ1-40
induces HSPG-mediated Ca2+ influx. Primary human VSMC were loaded
with fura II (10 μM) and treated with varying concentrations of Aβ1-40. In
some experiments, cells were pre-treated with active heparinase I (HpnI;
5 Sigma U/mL), washed, loaded with fura II, and treated with Aβ1−40.
Fluorescence was measured over ~10 minutes. Results are representative
of 3 independent experiments performed in triplicate. *p < 0.05 vs.
vehicle-treated control. (JPEG 44 kb)
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